SOX2-Driven Mechanisms in Glioblastoma Stem Cells

SOX2 is a high-mobility-group transcription factor that governs the identity and maintenance of glioblastoma stem cells (GSCs), a subpopulation within malignant gliomas responsible for tumour initiation, progression and resistance to therapy. By orchestrating a gene network that sustains pluripotency and inhibits differentiation, SOX2 drives self-renewal and promotes the invasive phenotype characteristic of aggressive tumours. Its expression is regulated at multiple levels, including promoter hypomethylation, gene amplification and post-translational modification. In GSCs, SOX2 cooperates with other stem-cell factors and chromatin remodellers to activate programmes of proliferation, survival and metabolic adaptation. Aberrant SOX2 activity enhances resistance to radiotherapy and chemotherapy, in part by engaging DNA-repair pathways and by reinforcing anti-apoptotic circuitry. Understanding how SOX2 stability and function are controlled in GSCs is crucial for the design of targeted therapies intended to deplete the stem-like compartment and improve patient outcomes.

Research from Nature Portfolio

Recent studies have revealed that SOX2 protein levels in patient-derived GSCs are maintained through competitive interactions between E3 ubiquitin ligases. One investigation demonstrated that TRIM26 binds SOX2 via its PRYSPRY domain, shielding it from polyubiquitination by the bona fide E3 ligase WWP2. Loss of TRIM26 led to increased SOX2 turnover, disruption of the downstream transcriptional network and impaired GSC self-renewal and tumour-forming capacity in vivo. These findings establish E3 ligase competition as a critical mechanism for SOX2 stabilisation and GSC maintenance, highlighting novel post-translational checkpoints for therapeutic intervention.

SOX2-Driven Mechanisms in Glioblastoma Stem Cells publication trend

The graph below shows the total number of articles in sox2-driven mechanisms in glioblastoma stem cells across all publications each year (not limited to Nature Index journals).

Technical terms

SOX2: A transcription factor of the SRY-box family essential for stem-cell maintenance and neural lineage specification.

Glioblastoma stem cells (GSCs): A subpopulation of tumour cells with stem-like properties, capable of self-renewal, differentiation and tumour propagation.

Polyubiquitination: The covalent attachment of multiple ubiquitin molecules to a protein, often marking it for proteasomal degradation.

E3 ubiquitin ligase: An enzyme that recognises specific protein substrates and catalyses the transfer of ubiquitin from an E2 enzyme.

Promoter hypomethylation: Loss of DNA methylation at a gene promoter that can lead to increased transcriptional activity.

ChIP-seq: Chromatin immunoprecipitation followed by sequencing, a method for mapping protein-DNA interactions genome-wide.

References

1. Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma. Nature Communications (2021).
2. Targeting SOX2 as a Therapeutic Strategy in Glioblastoma. Frontiers in Oncology (2016).
3. Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas. PLOS ONE (2011).
4. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics (2011).